Assessment of analgesia and adverse effects of controlled release tramadol and dihydrocodeine in patients with cancer pain - Based on a modified ESAS;Ocena analgezji i objawów niepoz̊adanych tramadolu i dihydrokodeiny o kontrolowanym uwalnianiu u chorych z bólem nowotworowym - Na podstawie zmodyfikowanej skali ESAS

Wspolczesna Onkologia

Volumn 12, Issue 5, 2008, Pages 246-254

  Leppert, Wojciech ^a   Majkowicz, Mikołaj ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Akademia Medyczna   (Poland)

Author keywords

Cancer pain; Dihydrocodeine; Tramadol; Treatment

Indexed keywords

CONTINUS; DIHYDROCODEINE; DIPYRONE; KETOPROFEN; PARACETAMOL; TRAMADOL; TRAMAL RETARD; UNCLASSIFIED DRUG;

ANALGESIA; ANXIETY; APPETITE; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG PREFERENCE; DYSPNEA; HUMAN; NAUSEA; PAIN ASSESSMENT; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; SENSATION; SIDE EFFECT; TREATMENT DURATION; VISUAL ANALOG SCALE; VOMITING; WELLBEING;

EID: 58749084861     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988; 38: 877-80.
2. Vickers MD, O'Flaherty D, Szekely SM, Read M, Yoshizumi J. Tramadol: pain relief by an opioid without depression of respiration. Anaesthesia 1992; 47: 291-6.
3. Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 1991; 27: 7-17.
4. Mathews S, Al-Mulla A, Varghese PK, Radim K, Mumtaz S. Postanaesthetic shivering - a new look at tramadol. Anaesthesia 2002; 57: 394-8.
5. Husslein P, Kubista E, Egarter C. Obstetrical analgesia with tramadol - results of a prospective randomized comparative study with pethidine. Z Geburtshilfe Perinatol 1987; 191: 234-7.
6. Hopkins D, Shipton EA, Potgieter D, Van derMerwe CA, Boon J, De Wet C, Murphy J. Comparison of tramadol and morphine via subcutaneous PCA following major orthopaedic surgery. Can J Anaesth 1998; 45 (5 Pt 1): 435-42.
7. Baraka A, Jabbour S, Ghabash M, Nader A, Khoury G, Sibai A. A comparison of epidural tramadol and epidural morphine for postoperative analgesia. Can J Anaesth 1993; 40: 308-13.
8. Miranda HF, Pinardi G. Antinociception, tolerance, and physical dependence comparison between morphine and tramadol. Pharmacol Biochem Behav 1998; 61: 357-60.
9. Stamer UM, Lehnen K, Höthker F, Bayerer B, Wolf S, Hoeft A, Stuber F. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231-8.
10. Gravenstein JS, Smith GM, Sphire RD, Isaacs JP, Beecher HK. Dihydrocodeine; further development in measurement of analgesic power and appraisal of psychologic side effects of analgesic agents. N Engl J Med 1956; 254: 877-85.
11. Keats AS, Telford J, Kurosu Y. Studies of analgesic drugs: Dihydrocodeine. J Pharmacol Exp Ther 1957; 120: 354-60.
12. Robertson JR. Dihydrocodeine: second strand of treatment for drug misusers. Drug Alcohol Rev 1996; 15: 200-1.
13. Wilder-Smith CH, Hufschmid E, Thormann W. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Br J Clin Pharmacol 1998; 45: 575-81.
14. Wotherspoon HA, Kenny GN, McArdle CS. Analgesic efficacy of controlled-release dihydrocodeine. A comparison of 60, 90 and 120 mg tablets in cold-induced pain. Anaesthesia 1991; 46: 915-7.
15. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008; 336: 199-201.
16. Wilder-Smith CH, Hill L, Spargo K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001; 91: 23-31.
17. Leppert W. The Role of Controlled Release Dihydrocodeine In The Treatment Of Cancer Pain, Polish Experience, Abstract of the 18th MASCC/ ISOO International Symposium, Supportive Care in Cancer, Toronto, Canada, June 22 - 25, 2006. Support Care Cancer 2006; 14: 657.
18. Bruera E, MacDonald S. Audit methods: The Edmonton Symptom Assessment System. In: Clinical Audit in Palliative Care. Higginson I (ed.). Radcliffe Medical Press, Oxford, New York 1993; 61-77.
19. Majkowicz M, Czuszynska Z, Leppert W, Maszkowska-Kopij J. Praktyczne wykorzystanie skali ESAS (Edmonton Symptom Assessment System) w opiece paliatywnej. Nowotwory 1998; 48: 847-57.
20. Mercadante S, Salvaggio L, Dardanoni G, Agnello A, Garofalo S. Dextropropoxyphene versus morphine in opioid-naive cancer patients with pain. J Pain Symptom Manage 1998; 15: 76-81.
21. Cossmann M, Wilsmann KM. Effect and side-effects of tramadol. Therapiewoche 1987; 37: 3475-85.
22. Lenzhofer R, Moser K. Analgesic effect of tramadol in patients with malignant diseases. Wien Med Wochenschr 1984; 134: 199-202.
23. Rodrigues N, Pereira ER. Tramadol in cancer pain. Curr Ther Res 1989; 46: 1142-8.
24. Osipova NA, Novikov GA, Beresnev VA, Loseva NA. Analgesic effect of tramadol in cancer patients with chronic pain: a comparison with prolonged - action morphine sulfate. Curr Ther Res 1991; 50: 812-21.
25. Grond S, Zech D, Lynch J, Schug S, Lehmann K. Tramadol - a weak opioid for relief of cancer pain. Pain Clinic 1992; 5: 241-7.
26. Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994; 5: 141-6.
27. Tawfik MO, Elborolossy K, Nasr F. Tramadol hydrochloride in the relief of cancer pain. A double blind comparison against sustained release morphine. Pain 1990; 55: S 377.
28. Brema F, Pastorino G, Martini MC, Gottlieb A, Luzzani M, Libretti A. Oral tramadol and buprenorphine in tumour pain. An Italian multicenter trial. Int J Clin Pharm Res 1996; 16: 109-16.
29. Bono AV, Cuffari S. Efficacité et tolérance du tramadol dans les douleurs néoplasiques. Etude comparative par rapportà la buprénorphine. Drugs 1997; 53, supl. 2: 40-9.
30. Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA. High - Dose Tramadol in Comparison to Low - Dose Morphine for Cancer Pain. J Pain Symptom Manage 1999; 18: 174-9.
31. Nossol S, Schwartzbold M, Stadler T. Treatment of pain with sustained - release tramadol 100, 150, 100 mg: results of a post - marketing surveillance study. Int J Clin Pract 1998; 52: 115-21.
32. Petzke F, Radbruch L, Sabatowski R, Karthaus M, Mertens A. Slow-release tramadol for treatment of chronic malignant pain - an open multicenter trial. Support Care Cancer 2000; 9: 48-54.
33. Łuczak J, Kotlińska A, Leppert W i wsp. Zastosowanie tramadolu (Tramalu) w zwalczaniu bólu nowotworowego. Nowotwory 1994; 44: 317-23.
34. Leppert W. Ocena przydatności analgetycznej i objaw_aacow ubocznych tramadolu i morfiny, podawanych droga doustna w leczeniu bólu nowotworowego. Praca na stopień doktora nauk medycznych. Akademia Medyczna w Poznaniu, Poznań 2000.
35. Leppert W. Rola analgetyków opioidowych II stopnia drabiny analgetycznej _aacSwiatowej Organizacji Zdrowia w leczeniu bólu nowotworowego. Onkol Pol 2006; 9: 145-8.
36. Mercadante S, Porzio G, Ferrera P, et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006; 31: 242-7.
37. Maltoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005; 13: 888-94.
38. Marinangeli F, Cicozzi A, Leonardis M, et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004; 27: 409-16.
39. Porta-Sales J, G_aacomez-Batista X, Tuca-Rodrigues A, et al. WHO analgesic ladder - or lift? Eur J Palliat Care 2003; 10: 105-9.
40. Leppert W. Łuczak J. The role of tramadol in cancer pain treatment - a review. Support Care Cancer 2005; 13: 5-17.
41. Dobrogowski J. Hilgier M. Kliniczna ocena działania DHC Continus u chorych z bólem przewleklym. Współcz Onkol 2003; 7: 528-34.
42. Schmidt H, Vormfelde SV, Klinder K, Gundert-Remy U, Gleiter CH, Skopp G, Aderjan R, Fuhr U. Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol 2002; 91: 57-63.
43. Viola R, Kiteley C, Lloyd NS, Mackay JA, Wilson J, Wong RK. Supportive Care Guidelines Group of the Cancer Care Ontario Program in Evidence-Based Care: The management of dyspnoea in cancer patients: a systematic review. Support Care Cancer 2008; 16: 329-37.
44. Luporini G, Barni S, Marchi E, Daffonchio L. Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur Respir J 1998; 12: 97-101.
45. Duggan AK. The cost of constipation in morphine patients and the economic possibilities with tramadol. Brit J Med Econom 1995; 9: 21-9.
46. Jurna I, Kömen W, Baldauf J, Fleischer W. Analgesia by dihydrocodeine is not due to formation of dihydromorphine: evidence from nociceptive activity in rat thalamus. J Pharmacol Exp Ther 1997; 281: 1164-70.
47. Webb JA, Rostami-Hodjegan A, Abdul-Manap R, Hofmann U, Mikus G, Kamali F. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. Br J Clin Pharmacol 2001; 52: 35-43.
48. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43: 879-923.
49. Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636-44.
50. Wilder-Smith CH, Bettiga A. The analgesic tramadol has minimal effect on gastrointestinal motor function. Br J Clin Pharmacol 1997; 43: 71-5.